Trevi Therapeutics
TRVI
16 hedge funds and large institutions have $53.5M invested in Trevi Therapeutics in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 16 → 16 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
2.25% less ownership
Funds ownership: 74.97% → 72.72% (-2.3%)
39% less capital invested
Capital invested by funds: $88M → $53.5M (-$34.6M)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$33.7K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.61K |
| 3 |
First Manhattan
New York
|
+$4.7K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$4.7K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$653 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$460K |
| 2 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$263K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$26.8K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$21.6K |
| 5 |
BlackRock
New York
|
-$7.49K |
TRVI Hedge Fund Activity: Q3 2020 in Review
16 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q3 2020, worth a combined $53.5M — down 39% from $88M a quarter earlier.
Fund positioning in TRVI was balanced in Q3 2020: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $33.7K. The largest seller was Banco Bilbao Vizcaya Argentaria, exiting entirely with an estimated $460K sold.
- 16 institutional investors held Trevi Therapeutics (TRVI) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $53.5M of Trevi Therapeutics stock for Q3 2020, down 39% quarter-over-quarter.
- 3 funds opened new Trevi Therapeutics positions in Q3 2020 and 3 closed out, a net change of 0 holders.
- The largest Trevi Therapeutics buyer in Q3 2020 was Geode Capital Management, an estimated $33.7K added.
- The largest Trevi Therapeutics seller in Q3 2020 was Banco Bilbao Vizcaya Argentaria, an estimated $460K sold.
Based on aggregated 13F filings for Q3 2020.